- Home
- WLAC vs EDIT Comparison
WLAC vs EDIT Comparison
Compare WLAC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLAC | EDIT |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 206.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | WLAC | EDIT |
|---|---|---|
| Price | $10.99 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $4.50 |
| AVG Volume (30 Days) | 230.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $784.60 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $9.96 | $0.91 |
| 52 Week High | $15.19 | $4.54 |
Technical Indicators
Market Signals| Indicator | WLAC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 38.39 |
| Support Level | $10.87 | $1.67 |
| Resistance Level | $11.32 | $1.83 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 13.06 | 15.22 |
Price Performance
Historical ComparisonAbout WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.